Rishi Rikhi

Dr. Rishi Rikhi

Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2022 in Atherosclerosis
Verified
Journal Article
Closed access
Rishi RikhiRishi Rikhi
Rishi Rikhi
AHAziz Hammoud
Aziz Hammoud
NANicklaus Ashburn
Nicklaus Ashburn
ASAnna C. Snavely
Anna C. Snavely
EMErin D. Michos
Erin D. Michos
MSMichael D Shapiro
Michael D Shapiro

15 November 2024 in JACC
Verified
Journal Article
Closed access
HBHarpreet S. Bhatia
Harpreet S. Bhatia
MDMarc R. Dweck
Marc R. Dweck
NCNeil Craig
Neil Craig
RCRomain Capoulade
Romain Capoulade
PPPhilippe Pibarot
Philippe Pibarot
STSotirios Tsimikas
Sotirios Tsimikas

1 February 2023 in Hypertension
Verified
Journal Article
Closed access
PDF file
Rishi RikhiRishi Rikhi
Rishi Rikhi
HBHarpreet S. Bhatia
Harpreet S. Bhatia
CSChristopher Schaich
Christopher Schaich
NANicklaus Ashburn
Nicklaus Ashburn
MTMichael Y. Tsai
Michael Y. Tsai
MSMichael D Shapiro
Michael D Shapiro
Background: This study explored the longitudinal relationship of Lp(a) (lipoprotein[a]) and hypertension to cardiovascular outcomes in a large multiethnic cohort free of baseline cardiovascular disease. Methods: Individuals from the MESA (Multi-Ethnic Study of Atherosclerosis; N=6674) were grouped as follows: group 1: Lp(a) <50 mg/dL and no hypertension; group 2: Lp(a) ≥50 mg/dL and no hypertension; group 3: Lp(a) <50 mg/dL and hypertension; and group 4: Lp(a) ≥50 mg/dL and hypertension. Kaplan-Meier curves and multivariable Cox proportional hazard models were used to assess the relationship of Lp(a) and hypertension with time to cardiovascular disease events. Results: Mean follow-up time was 13.9 (5.0) years and 809 participants experienced a cardiovascular disease event. A statistically significant interaction was found between Log[Lp(a)] and hypertension status ( P =0.091). Compared with the reference group (Lp[a] <50 mg/dL and no hypertension), those with Lp[a] ≥50 mg/dL and no hypertension had no increased risk for cardiovascular disease events (hazard ratio, 1.09 [95% CI, 0.79–1.50]). However, those with Lp(a) <50 mg/dL and hypertension or Lp(a) ≥50 mg/dL and hypertension demonstrated a statistically significant increase in risk compared to the reference group (hazard ratio, 1.66 [95% CI, 1.39–1.98]) and (hazard ratio, 2.07 [95% CI, 1.63–2.62]), respectively. Among those with hypertension, Lp(a) was associated with a significant increase in cardiovascular disease risk (hazard ratio, 1.24 [95% CI, 1.01–1.53]). Conclusions: Although the major contribution to cardiovascular risk was hypertension, elevated Lp(a) significantly modified the association of hypertension with cardiovascular disease. More research is needed to understand mechanistic links among Lp(a), hypertension, and cardiovascular disease.

20 June 2022 in IJC Heart & Vasculature
Verified
Journal Article
Open access
BBBrandon Bungo
Brandon Bungo
PCPulkit Chaudhury
Pulkit Chaudhury
MAMichael Arustamyan
Michael Arustamyan
Rishi RikhiRishi Rikhi
Rishi Rikhi
MHMuzna Hussain
Muzna Hussain
Rohit MoudgilRohit Moudgil
Rohit Moudgil
Atrial fibrillation (AF) is associated with an increased risk of stroke. Despite evidence linking cancer and thrombosis, cancer is not part of the CHA2DS2VASc score. Cancer is an independent risk factor for thromboembolic stroke in patients with AF. The SEER database was utilized to identify patients with lung, colon, breast, and prostate cancers with AF and no prior diagnosis of stroke and. compared to controls within the dataset. The primary endpoint was rates of stroke per 100 person-years. Cox regression modeling and a nested model comparing CHA2DS2VASc score (Model 1) with a complete model including cancer diagnosis (Model 2) were performed. Models were compared using Akaike Information Criterion (AIC) and Net Reclassification Index (NRI). A propensity-matched cohort with equivalent CHA2DS2VASc scores determining stroke-free survival was also performed. A total of 101,185 patients were included in the analysis, with 48,242 in the Cancer and 52,943 in the Non-cancer Group. Stroke rate per 100 person-years was significantly higher in the Cancer Group. The CHA2DS2VASc model (Model 1) was compared against a model including cancer (Model 2) showing improved predictability as assessed by both NRI and AIC. Cox regression analysis calculated a hazard ratio of 1.085 for Cancer, which was comparable to age >75, female sex, and diabetes. Propensity matched Kaplan-Meier curve demonstrated a decreased probability of stroke-free survival in the Cancer Group. Cancers increase the risk of stroke in patients with AF. Consideration should be given to the addition of cancer to the clinical scoring system.

1 August 2024 in Hypertension
Verified
Journal Article
Closed access
SMSaeid Mirzai
Saeid Mirzai
IPIan Persits
Ian Persits
RKRichard Kazibwe
Richard Kazibwe
MGMohanad Gabani
Mohanad Gabani
ASAustin Seals
Austin Seals
MSMichael D Shapiro
Michael D Shapiro
BACKGROUND: Sarcopenia and hypertension are independently associated with worse cardiovascular disease (CVD) risk and survival. While individuals with sarcopenia may benefit from intensive blood pressure (BP) control, the increased vulnerability of this population raises concerns for potential harm. This study aimed to evaluate clinical and safety outcomes with intensive (target <120 mm Hg) versus standard (<140 mm Hg) systolic BP targets in older hypertensive adults with sarcopenia compared with nonsarcopenic counterparts in the SPRINT (Systolic Blood Pressure Intervention Trial). METHODS: Sarcopenia was defined using surrogates of the lowest sex-stratified median of the sarcopenia index (serum creatinine/cystatin C×100) for muscle wasting and gait speed ≤0.8 m/s for muscle weakness. Outcomes included CVD events, all-cause mortality, and serious adverse events. RESULTS: Of 2571 SPRINT participants with sarcopenia index and gait speed data available (aged ≥75 years), 502 (19.5%) met the criteria for sarcopenia, which was associated with higher risks of CVD events (adjusted hazard ratio, 1.49 [95% CI, 1.15–1.94]; P =0.003) and all-cause mortality (adjusted hazard ratio, 1.46 [95% CI, 1.09–1.94]; P =0.010). In participants with sarcopenia, intensive (versus standard) BP control nearly halved the risk of CVD events (adjusted hazard ratio, 0.57 [95% CI, 0.36–0.88]; P =0.012) without increasing serious adverse events. Similar risk reduction was seen for all-cause mortality in participants with sarcopenia (adjusted hazard ratio, 0.66 [95% CI, 0.41–1.08]; P =0.102), but the effect was only significant in those without chronic kidney disease. CONCLUSIONS: Older hypertensive adults with sarcopenia randomized to intensive BP control experienced a lower risk of CVD without increased adverse events compared with standard BP control. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01206062.

1 November 2022 in Journal of Cardiopulmonary Rehabilitation and Prevention
Verified
Journal Article
Closed access
Rishi RikhiRishi Rikhi
Rishi Rikhi
MSMichael D Shapiro
Michael D Shapiro
Purpose: The objective of this report was to review the application of the pooled cohort equations in primary prevention and the assessment of cardiovascular health. Review Methods: Literature review was conducted using the PubMed database. In addition, the 2018 Multi-Society Guidelines on Management of Blood Cholesterol and the 2019 American College of Cardiology/American Heart Association Guidelines on the Primary Prevention of Cardiovascular Disease were reviewed. Summary: Primary prevention refers to individuals with no history of atherosclerotic cardiovascular disease, severe hypercholesterolemia, or diabetes. For these adults, aged 40-75 yr, who have a low-density lipoprotein-cholesterol of ≥70 mg/dL and <190 mg/dL, the pooled cohort equations should be used to provide a quantitative assessment of 10-yr atherosclerotic cardiovascular disease risk. From here, individuals are grouped as low risk (<5%), borderline risk (5 to <7.5%), intermediate risk (7.5 to <20%), or high risk (≥20%). Statin therapy should be strongly advised in those with an atherosclerotic cardiovascular disease risk of ≥20%, while statin therapy can be considered in those with a risk between 5% and <20%, especially if risk enhancing factors are present. If uncertainty still exists regarding treatment, a coronary artery calcium score can help further refine risk. All individuals, regardless of atherosclerotic cardiovascular disease risk, should have a cardiovascular health assessment using Life's Essential 8, which includes diet, physical activity, nicotine exposure, body mass index, blood glucose, blood lipids, blood pressure, and sleep.